Overview

Antenna’s media relations expertise allowed us to narrow in on the opioid crisis in order to leverage Bonti’s neurotoxin program and target key audiences worldwide.

Situation

  • Bonti developed a botulinum neurotoxin that can treat pain at its root cause.
  • Antenna was charged with debuting the clinical stage company to the media.

Approach

  • Antenna tapped into the news around the opioid epidemic to demonstrate the need for Bonti’s treatment.
  • We also leveraged existing widespread awareness of neurotoxins (e.g. Botox) to show how Bonti discovered a way to utilize neurotoxins for pain management, especially post-surgical.

Results

  • Antenna reached about 20M people in the first 60 days of engagement, communicating the importance of Bonti’s solution to both mainstream audiences and the medical community.

About

Bonti, a clinical-stage biotechnology company now acquired by Allergan, develops some of the most inventive medicines, devices, and procedures in the world, including a neurotoxin used to treat pain where it originates without the use of opioids.

Visit Website
The Antenna Ecosystem
Health
Main Service Performed
Public Relations
Other Services
Communications Strategy Media Relations
Share Case Study